Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL
CME INFORMATION

OVERVIEW OF ACTIVITY

Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. These events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.

Although original data are consistently being presented and published, the flood of information unveiled during a major academic conference is unmatched and leaves in its wake an enormous volume of new knowledge that practicing oncologists must try to sift through, evaluate and consider applying. Unfortunately and quite commonly, time constraints and an inability to access these data sets leave many oncologists struggling to ensure that they’re aware of crucial practice-altering findings. This creates an almost insurmountable obstacle for clinicians in community practice because they are not only confronted almost overnight with thousands of new presentations and data sets to consider but they are also severely restricted in their ability to review and interrogate the raw findings.

To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets on novel agents and therapeutic options for the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts may be applied to routine clinical care. This activity will assist medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES

• Appraise recent clinical research findings on the efficacy and safety of venetoclax alone or in combination for patients with CLL and FL.
• Compare the risks and benefits associated with the Bruton tyrosine kinase inhibitors ibrutinib and acalabrutinib for the treatment of CLL.
• Evaluate the activity and tolerability of obinutuzumab/bendamustine for patients with previously untreated CLL.
• Recall recent data on the activity of pembrolizumab in the treatment of relapsed/refractory CLL, including for patients with Richter’s transformation.
• Assess the safety of idelalisib in the front-line treatment of CLL.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCASH2016/2/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Jeff Sharman, MD
Director of Research, Willamette Valley Cancer Institute
Medical Director of Hematology Research
The US Oncology Network
Eugene, Oregon

Advisory Committee and Consulting Agreements: Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Pharmacyclics Inc; Contracted Research: Celgene Corporation, Cephalon Inc, Genentech BioOncology, Gilead Sciences Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodex Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc,
NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, CTI BioPharma Corp/Baxalta Inc, Jazz Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Seattle Genetics and Takeda Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2016
Expiration date: March 2017
Less than 2 weeks ago, in a historic act that will instantly affect the treatment of one of the most common hematologic cancers in general oncology practice, the FDA broadened the first-line indication of ibrutinib to now include patients both with and without 17p-deleted chronic lymphocytic leukemia (CLL). This landmark event is just part of an unprecedented explosion of new data and treatment options that have redefined the management of this disease over the past few years.

One of the many investigators in this worldwide effort is Dr Jeff Sharman, who first at Stanford and now in Springfield, Oregon has gained extensive practical experience working with many of the novel agents that are now part of current algorithms. I met with Jeff to learn about his perspectives — from both a clinical and a research standpoint — on relevant CLL and non-Hodgkin lymphoma data sets presented at the December ASH meeting and how these add to the rapidly evolving therapeutic paradigms in these cancers (click for the interview). Below find a summary of this conversation along with slides detailing the key findings from the ASH papers (click to review).

**RESONATE-2: Ibrutinib versus chlorambucil in untreated CLL**

In what might be compared to a matchup between the Green Bay Packers and my alma mater, Milford Mill High School, this randomized Phase III trial not surprisingly demonstrated the clear-cut superiority of the Bruton tyrosine kinase (BTK) inhibitor, with spectacular progression-free survival (PFS) and overall survival (OS) HRs of 0.16 for both endpoints. Although the trial focused on patients older than 65, the design and the results did not compel the FDA to tie an age stipulation to the recent approval expansion. In addition, ibrutinib had an acceptable safety profile, with the majority of adverse events being Grade 1 and a lower rate of treatment discontinuation due to toxicity compared to chlorambucil (9% versus 23%). As such, many, including Dr Sharman, believe ibrutinib will become the standard first-line treatment for most patients with CLL. He pointed out that the one exception might be younger patients with IgVH-mutated disease without high-risk FISH findings in whom a chemoimmunotherapy regimen like fludarabine/cyclophosphamide/rituximab (FCR) could potentially result in a prolonged remission or cure without the need for continuous treatment.
In discussing how the indefinite use of up-front ibrutinib may affect clinical practice, Dr Sharman focused on the need to pay even greater attention to the variety of treatment-related complications and potential adverse drug-drug interactions (discussed in another ASH report) that might lead to temporary discontinuation of this generally well-tolerated therapy. His concern in this regard stems from recent research demonstrating that treatment interruption for even 8 days has been associated with a reduction in PFS, a cautionary tale about the potential challenges of administering this or almost any agent indefinitely.

**Acalabrutinib (acala-B): A better BTK inhibitor?**

The extraordinary efficacy of acala-B might or might not exceed that of ibrutinib, but perhaps of equal importance is the hope that the safety profile may be superior, with early-onset headaches being the most common problem rather than the arthralgias, bruising, bleeding and atrial fibrillation observed with ibrutinib. In a Phase I/II trial of 60 evaluable patients with relapsed disease, responses were observed in 95% of patients, including all 18 with del(17p). A head-to-head Phase III trial will compare these relatively close cousins, but Dr Sharman believes this is another novel agent churning its way steadily toward approval.

**Idelalisib in CLL**

In one of the highlights of the late-breaking abstract session, Dr Andrew Zelenetz presented results of a Phase III trial evaluating bendamustine/rituximab (BR) alone or with idelalisib in relapsed/refractory (R/R) disease. The study, which was stopped early...
based on “overwhelming efficacy,” demonstrated an impressive improvement in both PFS (HR 0.33) and OS (HR 0.55), and the findings were consistent for patients with or without high-risk features. Although Dr Sharman questions whether bendamustine really adds much to idelalisib/rituximab, he does consider BR/idelalisib a rational option in the R/R setting.

Importantly, another study at ASH — idelalisib up front combined with ofatumumab — revealed an overall response rate (ORR) of 100% among 24 patients but an excess of immune-related adverse events such as hepatitis, pneumonitis and colitis. Dr Sharman believes these toxicities are likely related to the drug’s inhibition of regulatory T cells and explained that the lower frequency of idelalisib-related immune toxicity in the R/R setting may be the result of what he calls “immuno-plegia” as a consequence of prior therapies such as FCR. As a direct result of these new toxicity findings, just yesterday the FDA announced that 6 ongoing combination trials involving idelalisib and a number of other anti-cancer agents had been stopped.

**Venetoclax in CLL**

Although it is still in clinical development, the emergence of this highly effective Bcl-2 inhibitor represents another gigantic recent CLL advancement, and in Orlando we saw more impressive data with this agent in del(17p) disease with an ORR of 79.4% among 107 patients with R/R disease. We were also treated to some encouraging findings with combination regimens that included bendamustine, rituximab and obinutuzumab (obin) administered prior to, after or with the Bcl-2 inhibitor.

The FDA has now bestowed not 1 but 2 breakthrough therapy designations upon the drug in CLL, and Dr Sharman believes that the overwhelming database supporting the useful clinical role of this agent will likely lead to its approval this year. However, he and others remain somewhat concerned about the potential for tumor lysis syndrome (TLS), which was observed in early trials, and would like to see specific recommendations emerge for how to prevent or manage this phenomenon. In that regard, he believes that we will likely be assessing pretreatment tumor burden and renal function to determine baseline risk for TLS and then aggressively monitoring or even hospitalizing select patients. With that being said, the availability of another profoundly effective agent with a totally different mechanism of action has the entire CLL investigator community wide eyed with excitement over the possibility of long-term or lifelong disease control.

**Obinutuzumab in CLL**

It will be interesting to see how the role of this novel anti-CD20 antibody evolves with ibrutinib rapidly moving in on its indicated turf and the current/emerging treatment roster loaded with other novel small agents. Regardless, many believe this drug has good activity in CLL (likely more than rituximab) and for that reason were excited to determine how it would fare in combination with bendamustine. At ASH we saw more
from the single-arm GREEN study of bendamustine/obin in untreated and R/R disease demonstrating encouraging efficacy and acceptable toxicity with some concerns about TLS and neutropenia. In the current analysis of 158 patients with previously untreated disease, the bendamustine/obin combination yielded a complete response rate of 32.3%, with minimal residual disease negativity in blood and bone marrow of 58.9% and 28.5%, respectively. Despite these data, Dr Sharman believes the regimen is not yet ready for clinical practice in CLL. It is worth noting that on February 26 of this year the FDA approved bendamustine/obin followed by obin maintenance for patients with follicular lymphoma (FL) who did not respond to a rituximab-containing regimen.

**Pembrolizumab in CLL with Richter’s transformation (RT)**

RT occurs in approximately 2% to 10% of all CLL cases, and Dr Sharman commented that recently 2 patients in his practice died within 72 hours of diagnosis, in keeping with the often rapidly progressive course. In this preliminary ASH report of 5 patients with RT, 4 had mostly rapid and deep responses after receiving this anti-PD-1 antibody alone. Although it is clearly early days, Jeff found the findings so encouraging that he recently initiated treatment outside a trial setting with this agent in a patient with RT.

**ASH disappointments in indolent lymphoma (ibrutinib, venetoclax)**

With all the excitement in CLL, the ASH papers focused on indolent lymphomas were a bit underwhelming. In particular 2 studies in FL combining ibrutinib with either rituximab or rituximab/lenalidomide (R2) along with a couple of Phase I trials of venetoclax alone or with BR failed to inspire Dr Sharman, particularly when he considers how active idelalisib has been in this setting. He did find intriguing the significant activity observed with the Bcl-2 inhibitor in mantle-cell lymphoma, perhaps related to its biologic and therapeutic similarity to CLL.

Next on this series, Dr Michelle Fanale comments on other lymphoma papers from ASH, including more on the exciting findings now being reported with the use of checkpoint inhibitors in Hodgkin lymphoma.

Neil Love, MD

*Research To Practice*

Miami, Florida
Ibrutinib in Combination with Rituximab or Lenalidomide/Rituximab for Untreated FL

Presentations discussed in this issue


Ujjani CS et al. Phase I study of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma (Alliance 051103). Proc ASH 2015;Abstract 471.

Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Jeff Sharman, MD (2/9/16)

---

**Ibrutinib plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study**

**Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103)**

1 Fowler N et al. Proc ASH 2015;Abstract 470.

2 Ujjani CS et al. Proc ASH 2015;Abstract 471.
PCYC-1125-CA Trial: Ibrutinib/Rituximab in Follicular Lymphoma (FL)

- Multicenter, open-label Phase II study of ibrutinib 560 mg/d and rituximab 375 mg/m² weekly x 4
- N = 60 patients with treatment-naïve FL (Grade I, II and IIIA; Stage II to IV)
- **Primary endpoint:** Overall response rate (ORR)
- 12-month progression-free survival rate: 86%
  12-month overall survival rate: 98%


---

PCYC-1125-CA: Conclusions

- In treatment-naïve patients with FL, ibrutinib combined with 4 weekly infusions of rituximab demonstrated robust clinical activity with a high ORR of 82% and a complete response rate of 30%.
- The combination regimen was well tolerated; adverse events (AEs) were primarily Grade 1 or 2.
  - Grade ≥3 AEs: Fatigue (5%), maculopapular rash (5%), neutropenia (5%), hypertension (3%) and arthritis (3%)
- Further studies comparing the novel chemotherapy-free combination of ibrutinib and rituximab to standard regimens are being considered.

Investigator Commentary: Results from a Phase II Trial of Ibrutinib/Rituximab for Patients with Previously Untreated FL

In contrast to chronic lymphocytic leukemia, in which the activity of ibrutinib has transformed management of the disease, its activity and therefore role in the management of FL is considerably less robust. Several prior studies have demonstrated a moderate degree of activity of ibrutinib in FL, but none have identified a clear path to FDA approval. In that context, 2 studies reported at the ASH Annual Meeting explore ibrutinib in combination with other agents for previously untreated FL.

In the study by Nathan Fowler, ibrutinib was combined with rituximab. Ibrutinib was administered at 560 mg once daily until progressive disease or unacceptable toxicity. This was combined with rituximab weekly for 4 weeks. Participants were quite young, with the median age of 58 years suggesting some degree of patient selection bias. The ORR was 82% with a complete response rate of 30%. This appears to be a moderate improvement over rituximab monotherapy.

Continued

Investigator Commentary: Results from a Phase II Trial of Ibrutinib/Rituximab for Patients with Previously Untreated FL

Unfortunately, this improvement came at the cost of ibrutinib-related side effects, including diarrhea in about 50% of participants, rash, myalgias, bleeding and atrial fibrillation. Approximately 15% of patients in this study discontinued ibrutinib on account of side effects. We know from other studies that ibrutinib discontinuation increases with age and therefore is likely to be higher in a more typical treatment setting. Although this combination may get some use, it is not a significant step forward in the management of this disease.

Interview with Jeff Sharman, MD, February 9, 2016
Alliance 051103 Trial: Ibrutinib/Rituximab/Lenalidomide (IR²) in FL

- Multicenter, Phase I study of IR²
- N = 22 patients with treatment-naïve FL (Grade I to IIIA; Stage III, IV or bulky Stage II)
- **Key endpoints:** Tolerability and activity
- 12-month progression-free survival rate: 84%

<table>
<thead>
<tr>
<th>Overall response</th>
<th>Complete response</th>
<th>Partial response</th>
<th>Stable disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>95%</td>
<td>63%</td>
<td>32%</td>
<td>5%</td>
</tr>
</tbody>
</table>

Ujjani CS et al. *Proc ASH* 2015;Abstract 471.

Alliance 051103: Conclusions

- Preliminary response data were similar to those from the prior CALGB/Alliance multicenter study of lenalidomide/rituximab (R²).
- Given the increased toxicity and required dose modifications, the additional benefit of a third agent is not apparent:
  - 11/22 patients required dose reductions due to toxicity (7 due to rash)
  - 6 patients discontinued therapy because of AEs
  - Rash, diarrhea, arthralgia and neoplasms were all increased with IR² compared to R²
- Further investigation of the triplet in this setting seems unwarranted.

Ujjani CS et al. *Proc ASH* 2015;Abstract 471.
Investigator Commentary: Results from the Phase I Alliance 051103 Trial of IR^2 for Patients with Treatment-Naïve FL

In this study, ibrutinib was added to the combination of lenalidomide and rituximab (R^2). The R^2 regimen has shown dramatic activity in FL and might serve as a platform for the addition of ibrutinib. Response rates with the addition of ibrutinib did not greatly exceed those with the R^2 regimen. Unfortunately, it was also associated with rash in 82% of patients, with approximately one third experiencing Grade 3 rash.

Twelve of the 22 study participants discontinued treatment, in 6 cases because of adverse events. It is therefore unlikely that this regimen will change practice patterns, and it should not be considered outside of a clinical trial.

*Interview with Jeff Sharman, MD, February 9, 2016*